Cited by 103Drug Solubulity and Delivery SystemsAdvanced Drug Delivery SystemsDrug Transport and Resistance Mechanisms

Regional intestinal drug permeation: Biopharmaceutics and drug development

Lennernäs, Hans·2014·European Journal of Pharmaceutical Sciences

Abstract

Over the last 25 years, profound changes have been seen in both the development and regulation of pharmaceutical dosage forms, due primarily to the extensive use of the biopharmaceutical classification system (BCS) in both academia and industry. The BCS and the FDA scale-up and post-approval change guidelines were both developed during the 1990s and both are currently widely used to claim biowaivers. The development of the BCS and its wide acceptance were important steps in pharmaceutical science that contributed to the more rational development of oral dosage forms. The effective permeation (Peff) of drugs through the intestine often depends on the combined outcomes of passive diffusion and multiple parallel transport processes. Site-specific jejunal Peff cannot reflect the permeability of the whole intestinal tract, since this varies along the length of the intestine, but is a useful approximation of the fraction of the oral dose that is absorbed. It appears that drugs with a jejunal Peff>1.5×10(-4)cm/s will be completely absorbed no matter which transport mechanisms are utilized. In this paper, historical clinical data originating from earlier open, single-pass perfusion studies have been used to calculate the Peff of different substances from sites in the jejunum and ileum. More exploratory in vivo studies are required in order to obtain reliable data on regional intestinal drug absorption. The development of experimental and theoretical methods of assessing drug absorption from both small intestine and various sites in the colon is encouraged. Some of the existing human in vivo data are discussed in relation to commonly used cell culture models. It is crucial to accurately determine the input parameters, such as the regional intestinal Peff, as these will form the basis for the expected increase in modeling and simulation of all the processes involved in GI drug absorption, thus facilitating successful pharmaceutical development in the future. It is suggested that it would be feasible to use open, single-pass perfusion studies for the in vivo estimation of regional intestinal Peff, but that care should be taken in the study design to optimize the absorption conditions.

Integrity signals

Registry

Crossref · 10.1016/j.ejps.2013.08.025

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lennernäs, H.
Affiliations
Uppsala University (SE)
Corresponding author
Lennernäs, Hans
Venue
European Journal of Pharmaceutical Sciences
Publisher
Elsevier BV
Published
2014-06
Volume
57
Pages
333-341
ISSN
0928-0987 (ISSN-L)
OpenAlex
W2013095023
Cited by
103
References
94
Citations by year
2026: 7 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 9 · 2021: 8 · 2020: 11 · 2019: 8 · 2018: 11 · 2017: 14 · 2016: 6 · 2015: 12 · 2014: 4 · 2013: 1
FWCI
0.97
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Pharmaceutical Sciences (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
effective permeability, biowaiver, Biopharmaceutics Classification System, single-pass perfusion, oral drug absorption, passive diffusion, drug transport mechanisms, cell culture model
MeSH terms
Administration, Oral, Biological Availability, Biopharmaceutics, Dosage Forms, Pharmaceutical Preparations, Humans, Intestinal Absorption, Intestinal Mucosa, Models, Biological, Permeability, Pharmacokinetics, Solubility, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review